Apogee Therapeutics, Inc.
APGE
$39.94
$1.614.20%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -116.88% | -109.90% | -72.49% | -100.60% | -93.51% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 309.91% | -9.69% | -65.02% | -75.02% | -78.89% |
| Change in Net Operating Assets | -132.79% | -1.70% | -76.03% | -53.35% | -42.98% |
| Cash from Operations | -128.96% | -139.21% | -156.86% | -236.55% | -317.18% |
| Capital Expenditure | -589.82% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.34% | -64.46% | -- | -- | -- |
| Cash from Investing | -9.69% | -65.03% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 67.23% | 53.17% | -- | -- | -- |
| Repurchase of Common Stock | -15,234.27% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -1,185.35% | 100.00% | 100.00% |
| Cash from Financing | 56.98% | -7.94% | 333.71% | 328.80% | 71.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 170.53% | -134.69% | 36.31% | 129.40% | -120.08% |
